Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.

被引:103
|
作者
Walochnik, J
Duchêne, M
Seifert, K
Obwaller, A
Hottkowitz, T
Wiedermann, G
Eibl, A
Aspöck, H
机构
[1] Univ Vienna, Dept Pathophysiol, Div Specif Prophylaxis & Trop Med, AKH, A-1090 Vienna, Austria
[2] Univ Vienna, Clin Inst Hyg, Dept Med Parasitol, A-1090 Vienna, Austria
[3] Max Planck Inst Biophys Chem, Gottingen, Germany
关键词
D O I
10.1128/AAC.46.3.695-701.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Free-living amoebae of the genus Acanthamoeba are causing serious chronic conditions such as destructive keratitis in contact lens wearers or granulomatous amoebic encephalitis in individuals with compromised immune systems. Both are characterized by the lack of availability of sufficiently effective and uncomplicated, manageable treatments. Hexadecylphosphocholine (miltefosine) is licensed for use as a topical antineoplastic agent, but it is also active in vitro against several protozoan parasites, and it was applied very successfully for the treatment of human visceral leishmaniasis. The aim of our Study was to evaluate the efficacy of hexadecylphosphocholine and other alkylphosphocholines (APCs) against Acanthamoeba spp. The in vitro activities of eight different APCs against three Acanthamoeba strains of various pathogenicities were, determined. All substances showed at least amoebostatic effects, and some of them disrupted the amoebae, as shown by the release of cytoplasmic enzyme activity. Hexadecylphosphocholine exhibited the highest degree of cytotoxicity against trophozoites, resulting in complete cell death at a concentration as low as 40 muM, and also displayed significant cysticidal activity. Hexadecylphosphocholine may be: a promising new candidate for the topical treatment of Acanthamoeba keratitis and, conceivably, even for the oral treatment of granulomatous amoebic encephalitis.
引用
收藏
页码:695 / 701
页数:7
相关论文
共 50 条
  • [41] In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp.
    Biedenbach, Douglas J.
    Ross, James E.
    Putnam, Shannon D.
    Jones, Ronald N.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 2273 - 2275
  • [42] Quantification of Acanthamoeba spp. Motility
    Campolo, Allison
    Lara, Esther
    Crary, Monica
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2024, (211):
  • [43] Phylogenetic diversity among geographically dispersed Chlamydiales endosymbionts recovered from clinical and environmental isolates of Acanthamoeba spp.
    Fritsche, TR
    Horn, M
    Wagner, M
    Herwig, RP
    Schleifer, KH
    Gautom, RK
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2000, 66 (06) : 2613 - 2619
  • [44] Prevalence of Acanthamoeba spp. in Tasmanian intensive care clinical specimens
    Bradbury, R. S.
    French, L. P.
    Blizzard, L.
    JOURNAL OF HOSPITAL INFECTION, 2014, 86 (03) : 178 - 181
  • [45] On the diversity and clinical importance of Acanthamoeba spp. from Group 1
    Daniele Corsaro
    Parasitology Research, 2021, 120 : 2057 - 2064
  • [46] On the diversity and clinical importance of Acanthamoeba spp. from Group 1
    Corsaro, Daniele
    PARASITOLOGY RESEARCH, 2021, 120 (06) : 2057 - 2064
  • [47] Aerotolerance of human clinical isolates of Prevotella spp.
    Silva, VL
    Carvalho, MAR
    Nicoli, JR
    Farias, LM
    JOURNAL OF APPLIED MICROBIOLOGY, 2003, 94 (04) : 701 - 707
  • [48] Restriction endonucleases in clinical isolates of Shigella spp.
    Lee, KF
    Ling, JML
    Kam, KM
    Clark, DR
    Shaw, PC
    JOURNAL OF MEDICAL MICROBIOLOGY, 1997, 46 (11) : 949 - 952
  • [49] Yersiniabactin and other siderophores produced by clinical isolates of Enterobacter spp. and Citrobacter spp.
    Mokracka, J
    Koczura, R
    Kaznowski, A
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2004, 40 (01): : 51 - 55
  • [50] Aerotolerance of human clinical isolates of Prevotella spp.
    Farias, L.M. (macedo@icb.ufmg.br), 1600, Blackwell Publishing Ltd. (94):